Spherix will continue to collect monthly data on awareness, familiarity, use and uptake, timeline to trial, promotional effort, managed care trends, and projected use.

Source: https://www.prnewswire.com/news-releases/spherix-global-insights-continues-coverage-of-biogen--coherus-biosciences-ranibizumab-biosimilars-tracking-uptake-and-perceptions-of-the-first-commercially-available-biosimilars-to-genentechs-lucentis-301755717.htm